Compare Adaptive Biotechnologies Corp (ADPT) vs Chart Industries Inc (GTLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Chart Industries Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Chart Industries Inc trades at $209.15 (market cap $10.02B). The key difference: Chart Industries Inc is far larger — about 3× Adaptive Biotechnologies Corp's market cap, and Chart Industries Inc is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | GTLS | |
|---|---|---|
Market Cap | $3.33B | $10.02B |
Sector | Health | Technology |
52-Week High | $22.37 | $209.29 |
52-Week Low | $10.24 | $164.90 |
Enterprise Value | $3.19B | $13.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GTLS trades at $208.73 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The company reported $4.26B revenue for 2025 but has missed earnings expectations for three consecutive quarters, with negative profit margins and elevated valuation ratios. Recent news highlights Baker Hughes' pending $13.6B acquisition and new supply agreements supporting future growth.
Investment outlook remains mixed with strong analyst buy consensus (54%) offset by recent earnings underperformance. Key opportunities include acquisition premium potential and operational scale, while risks center on profitability challenges and integration execution. The stock's valuation appears stretched given current negative returns on equity and assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →
